CD38 and extranodal nasal NK/T cell lymphoma: A clinical trial (NCT02927925) showed that daratumumab, an anti-CD38 monoclonal antibody, achieved an overall response rate (ORR) of 25.0% in the treatment of relapsed or refractory NKTCL [27].